Farrell Simon - Mar 7, 2023 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Commercial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Mar 7, 2023
Transactions value $
$9,581
Form type
4
Date filed
3/8/2023, 03:00 PM
Previous filing
Feb 16, 2023
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $9.58K +18.8K +90.8% $0.51* 39.4K Mar 7, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -18.8K -25% $0.00 56.3K Mar 7, 2023 Common Stock 18.8K $0.51 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.